Pharming Group N.V.
Pharming Group N.V. (PHAR): 1 pipeline candidate. Updated within the last hour.
BioSniper Score
3-factor signal · derived from public data
N/A
0% dilution
Lead: Approved
1 candidate
N/A
N/A
A transparent, data-derived signal for Pharming Group N.V.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$905.1M
Cash
—
Quarterly Burn
$180.3M
Runway
—
Revenue
$376.1M
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| joenja | Approved |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
8
Total value held
$568K
| Holder | Shares | Value |
|---|---|---|
| morgan stanley | 11,489 | $191K |
| smartharvest portfolios, llc | 10,797 | $180K |
| citadel advisors llc | 10,189 | $170K |
| eversource wealth advisors, llc | 1,997 | $17K |
| bnp paribas financial markets | 400 | $7K |
| osaic holdings, inc. | 128 | $2K |
| stone house investment management, llc | 79 | $1K |
| cornerstone financial management llc | 32 | $532 |
Frequently asked questions
How many drug candidates are in Pharming Group N.V.'s pipeline?
Pharming Group N.V. (PHAR) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Pharming Group N.V.'s lead drug candidate?
Pharming Group N.V.'s most advanced tracked candidate is joenja (Approved) for 1 INDICATIONS AND USAGE JOENJA is indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older. JOENJA is a kinase inhibitor indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older. ( 1 ).
What is Pharming Group N.V.'s market capitalization?
Pharming Group N.V.'s market capitalization is approximately $905.1M.
Who is the CEO of Pharming Group N.V.?
Mr. Fabrice Chouraqui M.B.A., Ph.D., Pharm.D. is the chief executive officer of Pharming Group N.V. (PHAR).
Get the full picture on Pharming Group N.V.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.